Treatment persistence and discontinuation with rivaroxaban, dabigatran, and warfarin for stroke prevention in patients with non-valvular atrial fibrillation in the United …
CI Coleman, M Tangirala, T Evers - PLoS One, 2016 - journals.plos.org
A retrospective cohort analysis of the US MarketScan claims databases was performed to
compare persistence and discontinuation rates between the vitamin K antagonist warfarin …
compare persistence and discontinuation rates between the vitamin K antagonist warfarin …
Effectiveness and safety of non–vitamin K antagonist oral anticoagulants for atrial fibrillation and venous thromboembolism: a systematic review and meta-analyses
Purpose The findings from the observational studies comparing the effectiveness and safety
of non–vitamin K antagonist oral anticoagulants (NOACs) versus vitamin K antagonists …
of non–vitamin K antagonist oral anticoagulants (NOACs) versus vitamin K antagonists …
Non-vitamin K antagonist oral anticoagulation agents in anticoagulant naive atrial fibrillation patients: Danish nationwide descriptive data 2011–2013
Aims Non-vitamin K antagonist oral anticoagulation (NOAC) agents have been approved for
stroke prophylaxis in atrial fibrillation (AF). We investigated 'real-world'information on how …
stroke prophylaxis in atrial fibrillation (AF). We investigated 'real-world'information on how …
Comparison of clinical outcomes of edoxaban versus apixaban, dabigatran, rivaroxaban, and vitamin K antagonists in patients with atrial fibrillation in Germany: a real …
XL Marston, R Wang, YC Yeh, L Zimmermann… - International journal of …, 2022 - Elsevier
Background The aim of the study was to compare the real-world effectiveness and safety in
atrial fibrillation (AF) patients treated with edoxaban versus other oral anticoagulants …
atrial fibrillation (AF) patients treated with edoxaban versus other oral anticoagulants …
Association between use of non–vitamin K oral anticoagulants with and without concurrent medications and risk of major bleeding in nonvalvular atrial fibrillation
Importance Non–vitamin K oral anticoagulants (NOACs) are commonly prescribed with other
medications that share metabolic pathways that may increase major bleeding risk. Objective …
medications that share metabolic pathways that may increase major bleeding risk. Objective …
Non-vitamin K antagonist oral anticoagulants and major bleeding-related fatality in patients with atrial fibrillation and venous thromboembolism: a systematic review …
D Caldeira, FB Rodrigues, M Barra, AT Santos… - Heart, 2015 - heart.bmj.com
Objective Non-vitamin K antagonist oral anticoagulants (NOACs) are efficacious and safe
antithrombotic drugs but the non-availability of an antidote for potential fatal haemorrhagic …
antithrombotic drugs but the non-availability of an antidote for potential fatal haemorrhagic …
Comparative effectiveness and safety of non-vitamin K antagonists for atrial fibrillation in clinical practice: GLORIA-AF Registry
GYH Lip, A Kotalczyk, C Teutsch, HC Diener… - Clinical research in …, 2022 - Springer
Background and purpose Prospectively collected data comparing the safety and
effectiveness of individual non-vitamin K antagonists (NOACs) are lacking. Our objective …
effectiveness of individual non-vitamin K antagonists (NOACs) are lacking. Our objective …
Long-term comparative effectiveness and safety of dabigatran, rivaroxaban, apixaban and edoxaban in patients with atrial fibrillation: A nationwide cohort study
M Grymonprez, TL De Backer, X Bertels… - Frontiers in …, 2023 - frontiersin.org
Background: Although non-vitamin K antagonist oral anticoagulants (NOACs) are
recommended over vitamin K antagonists (VKAs) in atrial fibrillation (AF) management …
recommended over vitamin K antagonists (VKAs) in atrial fibrillation (AF) management …